Table 2.
Abnormal laboratory results for COVID-19 patients and CAP patients.
| Variate | COVID-19 (n = 296) | CAP (n = 130) | p |
|---|---|---|---|
| CD3+ | <0.001 | ||
| Normal | 185 (62.5%) | 56 (43.1%) | |
| High | 0 (0%) | 2 (1.5%) | |
| Low | 111 (37.5%) | 72 (55.4%) | |
|
| |||
| CD19+ | 0.032 | ||
| Normal | 81 (27.4%) | 35 (26.9%) | |
| High | 0 (0%) | 3 (2.3%) | |
| Low | 215 (72.6%) | 92 (70.8%) | |
|
| |||
| CD3+CD4+ | <0.001 | ||
| Normal | 217 (73.3%) | 59 (45.4%) | |
| High | 0 (0%) | 1 (0.8%) | |
| Low | 79 (26.7%) | 70 (53.8%) | |
|
| |||
| CD3+CD8+ | 0.216 | ||
| Normal | 140 (47.3%) | 55 (42.3%) | |
| High | 0 (0%) | 1 (0.8%) | |
| Low | 156 (52.7%) | 74 (56.9%) | |
|
| |||
| CD16+CD56+ | 0.008 | ||
| Normal | 129 (43.6%) | 39 (30%) | |
| Low | 167 (56.4%) | 91 (70%) | |
|
| |||
| 4/8 ratio | <0.001 | ||
| Normal | 169 (57.1%) | 58 (44.6%) | |
| High | 88 (29.7%) | 26 (20%) | |
| Low | 39 (13.2%) | 46 (35.4%) | |
|
| |||
| CD3+% lym | 0.679 | ||
| Normal | 153 (51.7%) | 70 (53.8%) | |
| High | 139 (47%) | 57 (43.8%) | |
| Low | 4 (1.4%) | 3 (2.3%) | |
|
| |||
| CD19+% lym | 0.004 | ||
| Normal | 164 (55.4%) | 66 (50.8%) | |
| High | 15 (5.1%) | 19 (14.6%) | |
| Low | 117 (39.5%) | 45 (34.6%) | |
|
| |||
| CD3+CD4+% lym | <0.001 | ||
| Normal | 106 (35.8%) | 69 (51.1%) | |
| High | 189 (63.9%) | 45 (36.7%) | |
| Low | 1 (0.3%) | 16 (12.2%) | |
|
| |||
| CD3+CD8+% lym | <0.001 | ||
| Normal | 264 (89.2%) | 88 (67.7%) | |
| High | 15 (5.1%) | 34 (26.2%) | |
| Low | 17 (5.7%) | 8 (6.2%) | |
|
| |||
| CD16+CD56+% lym | 0.018 | ||
| Normal | 231 (78%) | 88 (67.7%) | |
| High | 16 (5.4%) | 5 (3.8%) | |
| Low | 49 (16.6%) | 37 (28.5%) | |